Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

December 1, 2025

Study Completion Date

March 30, 2026

Conditions
Kidney Transplant Immunosuppression
Interventions
DRUG

Belatacept

Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.

Trial Locations (1)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CareDx

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT04786067 - Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression | Biotech Hunter | Biotech Hunter